Page last updated: 2024-10-29

staurosporine aglycone and Huntington Disease

staurosporine aglycone has been researched along with Huntington Disease in 1 studies

staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Apostol, BL1
Simmons, DA1
Zuccato, C1
Illes, K1
Pallos, J1
Casale, M1
Conforti, P1
Ramos, C1
Roarke, M1
Kathuria, S1
Cattaneo, E1
Marsh, JL1
Thompson, LM1

Other Studies

1 other study available for staurosporine aglycone and Huntington Disease

ArticleYear
CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
    Molecular and cellular neurosciences, 2008, Volume: 39, Issue:1

    Topics: Animals; Animals, Genetically Modified; Brain-Derived Neurotrophic Factor; Carbazoles; Cell Line; Di

2008